









市场行情
/
股票
/
nasdaq-arvn
/

Arvinas Inc

ARVN

12.160USD

-0.010-0.08%

收盘 12/26, 16:00（美东）报价延迟15分钟

860.93M总市值

亏损市盈率 TTM



Arvinas Inc

12.160

-0.010-0.08%

概览公司财务分析

概览

公司

财务

分析

关于 Arvinas Inc 公司

Arvinas, Inc. is a clinical-stage biotechnology company. The Company, through its PROteolysis Targeting Chimera (PROTAC) protein degrader platform, is pioneering the development of protein degradation therapies designed to harness the body’s natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. It is progressing multiple investigational drugs through clinical development programs, including vepdegestrant, ARV-393 and ARV-102. Vepdegestrant is an investigational orally bioavailable PROTAC protein degrader designed to target and degrade the ER for the treatment of patients with locally advanced or metastatic ER+/HER2- breast cancer. It is co-developing vepdegestrant with Pfizer. ARV-393 is an investigational, orally bioavailable PROTAC designed to degrade BCL6, a transcriptional repressor and a key regulator of normal B-cell maturation and differentiation processes. ARV-102 is in development to treat neurodegenerative diseases.

Arvinas Inc简介



公司代码ARVN

公司名称Arvinas Inc

上市日期Sep 27, 2018

CEODr. John G. Houston, Ph.D.

员工数量430

证券类型Ordinary Share

年结日Sep 27

公司地址5 Science Park

城市NEW HAVEN

上市交易所NASDAQ Global Select Consolidated

国家United States of America

邮编06511-1966

电话12035351456

网址https://www.arvinas.com/

公司代码ARVN

上市日期Sep 27, 2018

CEODr. John G. Houston, Ph.D.

Arvinas Inc公司高管



名称

名称/职务

职务

持股

持股变动

Dr. John G. Houston, Ph.D.

Chairman of the Board, President, Chief Executive Officer

912.27K

-7.52%

Dr. Angela Cacace, Ph.D.

Chief Scientific Officer

74.86K

-3.34%

Dr. Noah Berkowitz, M.D., Ph.D.

Chief Medical Officer

66.81K

+827.20%

Ms. Leslie V. Norwalk, Esq.

Independent Director

26.05K

+159.93%

Mr. Everett V. Cunningham

Independent Director

26.05K

+159.93%

Dr. Sunil Agarwal, M.D.

Independent Director

24.67K

+185.35%

Mr. Edward (Ted) Kennedy, Jr.

Independent Director

Ms. Linda C. Bain

Independent Director

Mr. Andrew Saik

Chief Financial Officer, Treasurer

Dr. Laurie Smaldone Alsup, M.D.

Independent Director

名称

名称/职务

职务

持股

持股变动

Dr. John G. Houston, Ph.D.

Chairman of the Board, President, Chief Executive Officer

912.27K

-7.52%

Dr. Angela Cacace, Ph.D.

Chief Scientific Officer

74.86K

-3.34%

Dr. Noah Berkowitz, M.D., Ph.D.

Chief Medical Officer

66.81K

+827.20%

Ms. Leslie V. Norwalk, Esq.

Independent Director

26.05K

+159.93%

Mr. Everett V. Cunningham

Independent Director

26.05K

+159.93%

Dr. Sunil Agarwal, M.D.

Independent Director

24.67K

+185.35%

收入明细

FY2025Q2

FY2025Q1

FY2024

FY2023

由于公司未披露，未能获取相关数据

地区USD

名称

营收

占比

United States

22.40M

0.00%

业务

地区

由于公司未披露，未能获取相关数据

股东统计

更新时间: 11月18日周二

持股股东

股东类型

持股股东

占比

The Vanguard Group, Inc.

13.31%

BlackRock Institutional Trust Company, N.A.

8.05%

Pfizer Inc

5.38%

D. E. Shaw & Co., L.P.

5.30%

Logos Global Management LP

3.89%

其他

64.05%

持股股东

占比

The Vanguard Group, Inc.

13.31%

BlackRock Institutional Trust Company, N.A.

8.05%

Pfizer Inc

5.38%

D. E. Shaw & Co., L.P.

5.30%

Logos Global Management LP

3.89%

其他

64.05%

股东类型

持股股东

占比

Investment Advisor

38.86%

Hedge Fund

26.19%

Investment Advisor/Hedge Fund

19.72%

Venture Capital

6.56%

Corporation

5.38%

Research Firm

4.23%

Individual Investor

2.59%

Pension Fund

0.46%

Bank and Trust

0.31%

机构持股



更新时间: 12月8日周一

报告期

机构数

持股数

持股占比

持股变动

2025Q4

513

61.93M

168.36%

-2.99M

2025Q3

525

64.92M

150.53%

-4.18M

2025Q2

518

67.55M

122.76%

+4.71M

2025Q1

504

63.19M

117.99%

-22.92M

2024Q4

484

75.18M

115.79%

+228.04K

2024Q3

476

75.20M

114.63%

+1.35M

2024Q2

469

73.21M

109.58%

+2.16M

2024Q1

476

70.86M

103.71%

+13.21K

2023Q4

483

66.87M

80.36%

+15.93M

2023Q3

458

50.77M

99.64%

+2.00M

股东持股明细



名称

持股数

占比

持股变动

变动比例

公告日期

The Vanguard Group, Inc.

9.38M

12.78%

+1.03M

+12.34%

Jun 30, 2025

BlackRock Institutional Trust Company, N.A.

5.26M

7.16%

+221.27K

+4.39%

Jun 30, 2025

Pfizer Inc

3.46M

4.71%

Jun 30, 2025

D. E. Shaw & Co., L.P.

2.15M

2.93%

+2.15M

Jun 30, 2025

Logos Global Management LP

4.80M

6.54%

+1.50M

+45.45%

Aug 18, 2025

Millennium Management LLC

1.90M

2.59%

+587.75K

+44.85%

Jun 30, 2025

State Street Investment Management (US)

1.73M

2.36%

-163.87K

-8.64%

Jun 30, 2025

Geode Capital Management, L.L.C.

1.59M

2.16%

+48.30K

+3.14%

Jun 30, 2025

New Leaf Venture Partners LLC

1.59M

2.16%

Jun 30, 2025

持股ETF



更新时间: 12月6日周六

机构名称

占比

Direxion Daily Pharmaceutical & Medical Bl 3X ETF

1.76%

State Street SPDR S&P Pharmaceuticals ETF

1.65%

Virtus LifeSci Biotech Clinical Trials ETF

0.91%

Invesco NASDAQ Future Gen 200 ETF

0.7%

iShares U.S. Pharmaceuticals ETF

0.28%

Federated Hermes MDT Small Cap Core ETF

0.24%

Zacks Small/Mid Cap ETF

0.22%

iShares Health Innovation Active ETF

0.16%

ProShares Ultra Nasdaq Biotechnology

0.11%

Invesco RAFI US 1500 Small-Mid ETF

0.1%

Direxion Daily Pharmaceutical & Medical Bl 3X ETF

占比1.76%

State Street SPDR S&P Pharmaceuticals ETF

占比1.65%

Virtus LifeSci Biotech Clinical Trials ETF

占比0.91%

Invesco NASDAQ Future Gen 200 ETF

占比0.7%

iShares U.S. Pharmaceuticals ETF

占比0.28%

Federated Hermes MDT Small Cap Core ETF

占比0.24%

Zacks Small/Mid Cap ETF

占比0.22%

iShares Health Innovation Active ETF

占比0.16%

ProShares Ultra Nasdaq Biotechnology

占比0.11%

Invesco RAFI US 1500 Small-Mid ETF

占比0.1%

分红派息



近5年累计派现 0.00 美元

公告日期

分红计划

股权登记日

现金发放日

除权除息日

暂无数据

拆合股



公告日期

类型

比率

暂无数据

公告日期

类型

比率

暂无数据

常见问题

Arvinas Inc的前五大股东是谁？



Arvinas Inc 的前五大股东如下：
The Vanguard Group, Inc.持有股份：9.38M，占总股份比例：12.78%。
BlackRock Institutional Trust Company, N.A.持有股份：5.26M，占总股份比例：7.16%。
Pfizer Inc持有股份：3.46M，占总股份比例：4.71%。
D. E. Shaw & Co., L.P.持有股份：2.15M，占总股份比例：2.93%。
Logos Global Management LP持有股份：4.80M，占总股份比例：6.54%。